✦ LIBER ✦

Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner

✍ Scribed by Megan Cornelison; Elias J. Jabbour; Mary Alma Welch

Book ID: 116893282
Publisher: Frontline Medical Communications, Inc.
Year: 2012
Tongue: English
Weight: 374 KB
Volume: 10
Category: Article
ISSN: 1544-6794
DOI: 10.1016/j.suponc.2011.08.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of interleukin 11 on thromboc

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Ahmed Aribi; Hagop Kantarjian; Charles Koller; Deborah Thomas; Stefan Faderl; Gu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Management of adverse events associated

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

✍ Jabbour, E; Deininger, M; Hochhaus, A 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 423 KB

Management of adverse events associated

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

✍ Jabbour, E; Deininger, M; Hochhaus, A 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 58 KB

Front-Line Therapy With Second-Generatio

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

✍ Jabbour, E.; Kantarjian, H. M.; O'Brien, S.; Shan, J.; Quintas-Cardama, A.; Garc 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 126 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views